GSK: Zantac Settlement Was Big, But Removes Uncertainty

Pharmaceutical company to pay more than USD 2 billion to settle lawsuits over heartburn drug

Jay Lee 11 October, 2024 | 12:01AM
Facebook Twitter LinkedIn

Zantac

Wide-moat GSK GSK announced that it has agreed to pay as much as USD 2.2 billion (£1.68 billion) to settle the majority of lawsuits in US state courts involving claims that Zantac caused cancer. Although this amount is higher than we anticipated, it is still within the range of expectations. We maintain our £22/$54 fair value estimate. Shares rose nearly 7% on Oct. 10 after the news was released.

Key Morningstar Metrics for GSK

• Fair Value Estimate: £22/USD 54
• Morningstar Rating: 5 stars
• Morningstar Economic Moat Rating: Wide
• Morningstar Uncertainty Rating: Medium

This agreement resolves approximately 80,000, or 93%, of the pending cases in US state courts related to the heartburn drug. The company also announced a separate settlement of $70 million to resolve a "qui tam" complaint previously filed by Valisure.

 

What is the Impact of GSK's Earnings?

According to The Guardian, the 10 law firms representing the claimants are unanimously recommending that their clients accept the settlement, which is expected to be fully implemented by the end of the first half of next year. The company expects to recognize an incremental charge in its third quarter of £1.8 billion (USD 2.3 billion) for these settlements as well as the remaining 7% of pending state court product liability cases.

Although the magnitude of the settlement amount is large, this news removes a significant risk overhang for the company and should pave the way for investors to focus more on GSK’s product portfolio and pipeline potential instead of headlines.

 

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
GSK PLC1,305.50 GBX0.42Rating

About Author

Jay Lee  is a stock analyst at Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures